Presidential Executive Order Seeks to Expand Psychedelic Access for Tough-To-Treat Mental Illnesses
Key Clinical Summary
- A new US presidential executive order targets suicidality, major depressive disorder (MDD), and substance use disorder (SUD) by expanding access to psychedelic therapies, including LSD, MDMA, psilocybin, and ibogaine.
- The policy directs the US Food and Drug Administration (FDA) to provide priority review and Breakthrough Therapy designation and expands access through the Right to Try Act while addressing Schedule I handling requirements for clinicians and researchers.
- The order allocates $50M to a Texas ibogaine research initiative and highlights that US veterans, who have a suicide rate twice the national average, are already traveling abroad for ibogaine therapy at significant risk and cost, underscoring the need for clinician awareness of risks and benefits.
On Saturday, April 18, 2026, President Donald J. Trump signed an executive order titled “Accelerating Medical Treatments for Serious Mental Illness,” which aims to expand psychedelic therapy access for significant mental health issues, such as suicidality, major depressive disorder (MDD), and substance use disorder (SUD).
“Despite massive federal investment into researching potential advancements in mental health care and treatment, our medical research system has yet to produce approved therapies that promote enduring improvements in the mental health condition of these most complex patients,” reads the executive order. “Innovative methods are needed to find long-term solutions for these Americans beyond existing prescription medications.”
Policy Details
The order expands horizons for psychedelic therapy, including lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA), psilocybin, and more, by loosening federal restrictions that have inhibited rigorous scientific investigation into these agents since the launch of the modern War on Drugs by President Richard Nixon in the 1970s.
Further, it eases the process of developing these compounds for clinical use by granting priority review through FDA Breakthrough Therapy designation, and expanded patient access through the Right to Try Act, which will address “any necessary Schedule I handling authorizations for treating physicians and researchers.”
The order also authorized $50M in federal funding to Texas to support the state’s research initiative on ibogaine, a psychedelic from Central Africa that has grown in interest among addiction experts and veterans’ groups due to reports that a single therapy provided impressive symptom improvement in both populations.
The executive order expresses particular concern about US veterans, who as a group exhibit a suicide rate that is twice the national average for adults. A roughly estimated hundreds to thousands of US veterans travel to clinics in Mexico and other foreign locales to access ibogaine therapy, with a session costing between $5K to $15K.
Through this presidential action, the federal government is poised to rapidly transform the psychedelics field within mental health practice.
Expert Commentary
“I think it is likely that the executive order (EO) will profoundly impact mental health treatment by making psychedelics far more broadly available than would have been the case without it,” Charles Raison, MD, director of clinical and translations research at Usona Institute and Psych Congress Steering Committee Member, told Psych Congress Network.
“I think in addition to FDA approval, the EO will encourage ongoing state-level efforts to make legacy psychedelics, such as psilocybin, available to the widest possible group of people who might benefit, not just for the treatment of mental illness per se, but also for the enhancement of wellbeing.”
As the landscape for these treatments continues to evolve rapidly, clinicians will need to stay informed to best support their patients in clinical practice.
“Psychedelics have a long history of being politicized, which continues to shape patient interest, expectations, and trust,” said Jennifer Tustison, DNP, PMHNP-BC, FNP-C, Psych Congress Elevate faculty member and a private practice clinician who provides ketamine-assisted psychotherapy.
“In this context, the clinician’s role extends beyond understanding the treatments themselves. It also involves helping patients navigate a complex and sometimes polarized information landscape.
Approaching these conversations with transparency, humility, and a strong patient-centered focus will be essential to maintaining trust and supporting thoughtful, individualized decision-making as these treatments continue to develop.”
To learn more about the current landscape of psychedelic therapy in psychiatry, join Dr Raison and Dr Tustison at Psych Congress Elevate for their session “The Psychedelic Countdown: From Clinical Trials to Clinical Practice.”
References
Trump DJ. Accelerating Medical Treatments for Serious Mental Illness. April 18, 2026.
